Fluonic to Present at Leading Investor Conference in Denver

Share Article

The Colorado Capital Conference showcases digital health and information company.

News Image

The Rockies Venture Club has selected Fluonic, Inc., to present at the 26th annual Colorado Capital Conference Nov. 13, 2014, in Denver.

Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s products solve the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows.

The Colorado Capital Conference (CCC) is taking place at the offices of The Denver Post and has been a leading investor conference in Colorado for 26 years. The Rockies Venture Club has always hosted this historical event with the goal of connecting entrepreneurs and investors in Colorado. Attendees include angel investors, venture capitalists, entrepreneurs, service providers, and students. This year CCC focuses on Digital Health Care and more specifically, those companies that are pioneering in bringing efficiency and effectiveness to the health care industry by implementing revolutionary new technologies.

At the conference, Fluonic will discuss its technology and flagship product, the SURE+ fully disposable infusion system. The system, which measures the actual flow rate to the patient in real time, allows remote monitoring of the infusion procedure, and provides auto adjustments and alarms.

Creating a new standard of care
“The Colorado Capital Conference will give Fluonic the opportunity to present a cost-effective, scalable solution for a problem that has afflicted the health care industry for more than 30 years,” says Jim Kasic, CEO of Fluonic. While more than 90 percent of hospitalized patients receive some type of intravenous drug therapy, and hundreds of thousands more receive intravenous drug therapy at home or on an out-patient basis, the pumps that deliver the medication operate blindfolded, unable to verify what they actually deliver to the patient, he explains. The industry is plagued with recalls of hundreds of thousands of faulty pumps. “The situation is an unacceptable one for a life-dependent medical system,” says Kasic.

Fluonic’s sensor, Kasic states, is accurate over the entire flow range, delivers information on the medication flow to designated recipients, wirelessly, and senses very low flows very precisely. As a result, health care providers can better control infusion drug delivery, and patients can receive more types of drugs at home, effectively reducing hospital stays and visits, and outpatient clinic visits. “Fluonic is creating the opportunity for a new standard of care, taking the questions and guesswork out of infusion drug therapy.”

Fluonic, Inc. (http://www.fluonic.com)
Based in Boulder, Colo., Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s products, including the flagship VariFlow sensor, solve the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows. Initial applications include elastomeric infusion pumps and critical care equipment.
(end)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aimee Bennett

Jim Kasic